Pluristyx and the Advanced Regenerative Manufacturing Institute to Commercialize Clinical-Grade Stem Cells
Pluristyx, Inc. today announced an agreement with the Advanced Regenerative Manufacturing Institute | BioFabUSA to manufacture and commercialize Pluristyx’s clinical-grade reprogrammed induced Pluripotent Stem Cells (iPSCs).
- Pluristyx, Inc. today announced an agreement with the Advanced Regenerative Manufacturing Institute | BioFabUSA to manufacture and commercialize Pluristyx’s clinical-grade reprogrammed induced Pluripotent Stem Cells (iPSCs).
- This collaboration will make it possible to accelerate the scalable, consistent, and cost-effective manufacturing of stem cell derived products for patient administration.
- The agreement provides ARMI | BioFabUSA, its affiliates, and Members streamlined access to high-quality clinical grade- iPSCs for cell and gene therapy manufacturing.
- For more information on Pluristyx, please visit www.pluristyx.com
The Advanced Regenerative Manufacturing Institute (ARMI), headquartered in Manchester, NH, is a member-based, nonprofit organization whose mission is to advance the bioeconomy of the United States.